Conventional RECIST Might Underestimate Pembrolizumab Benefit for Melanoma
Source: Cancer Therapy Advisor, March 2016
Because of atypical responses, conventional Response Evaluation Criteria in Solid Tumors (RECIST) might underestimate the benefit of pembrolizumab in approximately 15% of patients treated for melanoma, a study published in the Journal of Clinical Oncology has shown.1
For the study, researchers sought to evaluate atypical response patterns and the association between overall survival and best overall response measured per immune-related response criteria (irRC) and RECIST version 1.1 in patients with advanced melanoma treated with pembrolizumab.
Investigators analyzed data from the phase 1b KEYNOTE-001 study, which enrolled 655 patients with melanoma. Participants received pembrolizumab 2 or 10 mg/kg IV every 2 or 3 weeks.